In glioblastomas, the presence of a constitutively active mutant epithelial growth factor receptor (EGFR), the EGFR variant III (EGFRvIII), functions as an enhancer of activated SREBP1 in the nucleus, being correlated with increased levels of FASN and ACC (Guo et al., 2009). Here, EGFR is linked to glioblastoma.